Breast Cancer

We are offering the following trials in partnership with the Seattle Cancer Care Alliance (SCCA):

• Combined Targeted Therapies for Triple Negative Advanced Breast Cancer – A Phase II Trial of Weekly Nab-Paclitaxel (Abraxane) and Bevacizumab (Avastin) Followed by Maintenance Targeted Therapy With Bevacizumab (Avastin) and Erlotinib (Tarceva)

• Phase II Trial of Metronomic Eribulin (Halaven) In Pretreated Metastatic Breast Cancer (MBC)

Contact: Christine Reed, 541-706-6592 or creed@bmctotalcare.com

Location: Bend, Oregon (Central Oregon)

For general inquiries, please contact the BMC Research Department at research@bmctotalcare.com or 877-692-8338.

Back to Clinical Research